Top

Develop and Validate Transferrin Receptor

Active

75N98026Q00866Federal

Response Deadline07/31/2026, 01:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(1)

NOI++Creative+Biolabs+75N98026Q00866_+%28002%29.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

PhasePresolicitation

PostedJul 24

Presolicitation

Response DeadlineJul 31

Submission deadline

Response Deadline

07/31/2026, 01:00:00 PM UTCin 7 days

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health Olao

View Agency Profile

Office AddressBETHESDA, MD, 20892, USA

Contacts

Towanda Daniels

contact@example.gov

Full Description

See attach Notice of Intent

(75N98026Q00866)

Similar Contracts

Same NAICS industry code

NAICS: 541714

New

Federal

Procurement of lateral flow (LFA) strips for the rapid HIV nucleic acid diagnostic testThe Centers for Disease Control and Prevention is seeking quotes for the procurement of lateral flow (LFA) strips to support a rapid HIV nucleic acid diagnostic test under solicitation number 75D30126Q79099. This is a combined synopsis and solicitation issued as a Request for Quote under FAR Subpart 12, governing commercial item acquisitions, and will result in a firm-fixed-price contract. The period of performance is set from August 1, 2026, through December 31, 2026, with performance taking place at the CDC’s facility located at 1600 Clifton Road, Building 17, Atlanta, Georgia. All submissions must be made in writing by 3:00 p.m. Eastern Standard Time on Friday, July 24, 2026, and no telephonic responses will be accepted. Offerors must be registered in the System for Award Management at the time of submission and are responsible for familiarizing themselves with applicable Federal Acquisition Regulation clauses, including 52.212-1 and 52.212-4. Questions must be submitted no later than close of business on Monday, July 23, 2026, to Eugene L. Gutierrez Jr. at zvm0@cdc.gov. The acquisition falls under NAICS code 541714 with no set-aside designated, and the quote format is flexible at the offeror’s discretion.

CDC Office Of Acquisition Services

POSTED

DEADLINE

Illumina Reagent Kits

Naval Medical Research Center

POSTED

DEADLINE

Battlefield Pain Management – AnalgesicThis solicitation under the Prototype Other Transaction Authority (10 U.S.C. § 4022) seeks innovative analgesic solutions for battlefield use, with the goal of achieving FDA approval for a single-use product intended to manage acute moderate to severe pain in combat settings. The product must be rapid to administer, compact in size and weight for individual carrying, and capable of functioning without refrigeration across extreme temperatures ranging from -25°C to 45°C while maintaining a 2-3 year shelf life at controlled room temperature. It must comply with USP <659> and MIL-STD-810 environmental standards, adhere to 21 CFR Part 820 quality system requirements for labeling and packaging, and meet strict physiological limits including no more than a 20% reduction in blood pressure, heart rate, or clotting ability, with only minor, non-ventilation-required airway changes. The product must be classified as a DEA Schedule II or higher controlled substance and may be delivered via nasal spray or autoinjector. The effort spans eight years, divided into three phases: three years for Chemistry Manufacturing Controls and stability studies, two years for non-clinical enabling studies, and three years for clinical trials and human factors testing culminating in potential EUA submission. The contract is structured as an Other Transaction Agreement exempt from FAR and DFARS, except where explicitly referenced, and is not subject to Bayh-Dole provisions. Proposals must demonstrate at least one of three pass/fail conditions: inclusion of a significant nontraditional defense contractor or nonprofit research institution, all non-federal participants being small businesses or nontraditional contractors, or at least one-third of project costs being privately funded. Evaluation focuses on technical approach, management strategy, and cost, with no assigned weights provided. Submission requires three clearly organized volumes in searchable PDF format, accompanied by a Microsoft Project plan, with strict formatting rules prohibiting embellishments. All participants must be registered in SAM with an active UEI and CAGE code, and must include NAICS code 541714. Compliance with prohibitions on malign foreign talent programs is mandatory, requiring certification and disclosure of foreign affiliations, ownerships, and funding sources. Payment occurs through WAWF using NPI, cost vouchers, or invoices tied to CLINs and ACRNs, with acceptance managed by an Agreement Officer Representative. Data deliverables, including CMC reports, clinical study outcomes, and regulatory filings, are governed by CDRL and DID attachments

Defense Health Agency

POSTED

DEADLINE

Development of Light-Responsive Artificial Cells using Plant-Based Photoreceptor SystemsThe United States Army Corps of Engineers Engineer Research and Development Center Construction Engineering Research Laboratory is seeking to develop light-responsive artificial cells by integrating plant-derived UVR8 photoreceptor systems into synthetic biology platforms, using high-throughput protein engineering and AI-assisted structural refinement to create programmable, pseudo-living systems activated by environmental light stimuli. The project aims to advance foundational science in synthetic biology by leveraging Bioconscientia, LLC’s uniquely specialized expertise in UVR8 photoreceptor technology, which enables precise sensing of UV-B light in a manner unmatched by other entities. Due to the highly specialized nature of the required research and Bioconscientia’s irreplaceable knowledge of existing experimental data and technical pathways, the government intends to award a sole-source contract to this vendor under RFO FAR 12.102(a), with an anticipated award date of September 30, 2026. This presolicitation notice, issued under FAR Part 5.101(a) with solicitation number W9132T26QA015 and NAICS code 541714, does not constitute a formal request for proposals or a competitive procurement, nor is it a set-aside. Interested parties may submit capability statements to CERL-CT-QUOTES@USACE.ARMY.MIL by July 31, 2026, to be reviewed for potential technical equivalency, but submission does not guarantee a change to the government’s acquisition strategy. The government retains full discretion to proceed with sole-source award regardless of responses received. All work will be performed in Champaign, Illinois, and the primary point of contact for submissions is Lurline L. Simmons, with Andrea J. Thomas serving as the contracting officer. No telephone inquiries will be accepted.

W2R2 Construction Engrg Labor

POSTED

DEADLINE

AI/ML and Data Analytics for Cardiovascular Device Validation

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is soliciting collaborative participation through a continuous, open Participant Basic Agreement (PBA) under the HEALER portfolio to advance next-generation, threat-agnostic host-directed therapeutics designed to enhance physiological resilience against CBRN threats. This initiative targets five critical biological systems—neurological protection, respiratory stabilization, immune modulation, hematologic and vascular function, and cellular stress and repair pathways—with the goal of developing dual-use medical countermeasures that serve both military and civilian critical care needs. The program invites two categories of collaborators: therapeutic developers with candidates that modulate host response mechanisms and drug development support providers including CROs and CDMOs with capabilities in preclinical testing, clinical trial execution, cGMP manufacturing, regulatory strategy, and advanced modeling. Submission requires a white paper of no more than five pages excluding a cover page, detailing product mechanism of action, efficacy data from validated animal models, regulatory status such as IND experience and clinical trial history, manufacturing capacity and scale-up plans, and company profile for therapeutic developers, or core capabilities and infrastructure for service providers. All participants must express willingness to collaborate with other PBA holders to foster an integrated development ecosystem. The solicitation, issued under statutory authority of 10 U.S.C. §§4021–4023, operates outside the Competition in Contracting Act and does not follow traditional procurement or evaluation frameworks, eliminating standard contract clauses, formal evaluation factors, pricing structures, or submission deadlines. Instead, awards are made at the government’s discretion through a non-traditional acquisition mechanism designed to accelerate innovation. Technical and administrative inquiries are directed to Hunter Robinson and Alexander Mayatte at the U.S. Army’s Aberdeen Proving Ground, Maryland office. Participation prerequisites include current registration in the System for Award Management (SAM), compliance with FDA regulatory pathways, and adherence to cGMP standards for manufacturing. While no specific delivery dates, FOB terms, inspection criteria, or cost estimates are defined, performance is expected to align with the mission of CPE CBRND to enable the Joint Force to operate effectively in CBRN-contested environments. Intellectual property considerations, teaming arrangements, and the scalability of therapeutic candidates are central to selection, with no socioeconomic or size status certifications required. The structure prioritizes agility, collaboration, and cross-sector innovation over rigid compliance, enabling a dynamic pipeline of medical countermeasures capable of addressing evolving biological threats through sustained host resilience.

POSTED

DEADLINE

Non-Optical Methods for High Speed Protein ControlDARPA’s Biological Technologies Office is seeking innovative solutions through the ERIS Marketplace to develop a new class of rapidly switchable, non-optogenetic protein domains capable of enabling real-time, massless control of cellular processes. The goal is to create a robust, modular molecular tool that responds to non-optical external signals such as magnetic fields or focused ultrasound, allowing precise regulation of protein function across cell membranes without relying on light or chemicals. Proposed solutions must achieve activation and deactivation kinetics of no more than two seconds, demonstrate reliable performance through at least 300 repetitive cycles in living cells, and function effectively in both split-protein dimerization and allosteric conformational configurations. This effort explicitly excludes any modifications or enhancements to existing optogenetic, light-based, or chemical systems. The anticipated contract value is $400,000 for a 12-month performance period, with awards being made on a rolling basis as solutions are evaluated, and the government reserves the right to issue awards before the December 8, 2026 submission deadline. Proposals must be submitted via the DARPA Connect ERIS Portal as a video that follows the required title format, or existing awardable solutions may be flagged for consideration by emailing ERIS@darpa.mil with specific subject and body requirements. Evaluation will focus on four core areas: a deep understanding of the problem space and current limitations in fields like sonogenetics and magnetogenetics, a significant technical leap in achieving rapid and repeatable protein control, demonstrated expertise in synthetic biology, protein engineering, and biophysics with a proven track record of quantitative in vivo characterization, and the potential of the solution to become a foundational tool in synthetic biology with broad applications in defense-relevant areas such as biomanufacturing, cell-based therapeutics, and biosensing. All submissions are subject to the ERIS assessment process, which serves as a mandatory pass/fail gate—only solutions deemed awardable by this process will be considered for BTO award. The procuring agency is the Department of Defense through DARPA’s Arlington, VA office, and all participants must comply with the ERIS Master Solicitation requirements available via SAM.gov.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Notice of Intent to Sole Source – University of Maryland Medical Center

National Institutes Of Health - Cc

POSTED

DEADLINE

Limited Competition: Clinical and Translational Science Awards (CTSA) Program: Collaborative and Innovative Acceleration AwardThe Congressionally mandated Clinical and Translational Science Awards (CTSA) Program aims to accelerate the translation of scientific discoveries into practical treatments, diagnostics, and health interventions that enhance patient and public health by funding a national network of academic medical centers. This network provides essential infrastructure, expertise, training, and collaborative platforms needed to move research from the laboratory into clinical practice and community health settings. The current opportunity is a forecast for a limited competition soliciting applications for the Collaborative and Innovative Acceleration Award, designed to support the development and implementation of novel approaches, technologies, or models that amplify the impact of translational research and expedite the delivery of effective therapies to all populations. Funding is authorized under Sections 301 and 405 of the Public Health Service Act, and governed by Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. Eligible organizations may apply under this limited competition, and proposals will undergo standard National Institutes of Health peer review, with funding awarded only to meritorious applications. The announcement is issued by the National Institutes of Health, under the Department of Health and Human Services, with specific inquiries directed to the Division of Clinical Innovation at NCATS. The forecast was posted on July 20, 2026, and further details can be accessed through the official grants.gov listing, though no set-aside type, NAICS code, or specific place of performance is indicated.

National Institutes Of Health

POSTED

DEADLINE

On-Site Technical Deployment and Integration

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber ServicesNASA Johnson Space Center is soliciting offers for Hypoxia Chamber Services under solicitation number 80JSC026Q0008 to support research on the physiological, cognitive, and clinical effects of mild hypobaric hypoxia as part of the Artemis Program. The contract requires comprehensive services including infrastructure, personnel, training, materials, food, supplies, and operational support necessary to conduct controlled hypoxia experiments. This is a combined synopsis and solicitation issued under FAR Subpart 12.6, with no written solicitation to follow, and all information is contained within the posted notice and attachments, particularly Attachment A for the Performance Work Statement and Attachment D for additional submission requirements. The NAICS code is 541714 with a size standard of 1,000 employees, and offerors must self-certify their size status. Evaluation will prioritize Technical Acceptability and Past Performance as significantly more important than Price, though Price becomes increasingly relevant when proposals are closely matched in technical merit. All submissions must include completed representations and certifications per FAR 52.212-3 and comply fully with FAR 52.212-1 and 52.212-4. Proposals must be submitted electronically via email to the designated NASA contacts no later than 1:00 PM CST on August 24, 2026, with questions due by July 29, 2026. The Government assumes no responsibility for electronic submission failures, and late submissions will be rejected per FAR provisions. The place of performance is Houston, Texas, and the Ombudsman clause is applicable for dispute resolution.

NASA Johnson Space Center

POSTED

DEADLINE

Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain BarrierThe Eunice Kennedy Shriver National Institute of Child Health and Human Development is advancing its mission to improve maternal, fetal, and child health by launching a second phase of the Transporter Elucidation Network, focused on understanding how biological transporters and local metabolic processes regulate exposure to nutrients, medications, microbiome-derived compounds, and environmental chemicals across critical perinatal barriers. This initiative will develop comprehensive multi-barrier frameworks that connect the maternal gut, placenta, lactating mammary epithelium, infant gut, and infant blood-brain barrier, building on prior organ-specific research to create standardized models, resources, and prototype multi-compartment systems that reflect the dynamic interplay of transporters, their polarity, kinetics, and biotransformation capacities during pregnancy, lactation, and infant development. The goal is to deepen mechanistic insights into how these systems influence nutrient delivery, drug distribution, and neurodevelopmental outcomes in early life. This phase will establish community-wide resources to support integrated studies of perinatal exposure, risk assessment, and targeted interventions across linked maternal-fetal-infant systems, while strengthening collaboration among researchers and accelerating the sharing of tools and data. Emphasis is placed on human-based and developmentally relevant models to ensure biological accuracy and translational impact. The effort also aims to cultivate a next-generation workforce skilled in transporter science, fostering innovation in pediatric pharmacology and neonatal health. Authorized under 42 U.S.C. § 241, the initiative is being led by the Obstetric and Pediatric Pharmacology and Therapeutics Branch of NICHD, with inquiries directed to their designated point of contact, and the opportunity was publicly forecasted on July 16, 2026.

National Institutes Of Health

POSTED

9 days ago

DEADLINE

N/A

View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

NAICS: 811210

New

Federal

Preventive Maintenance for Gatan BioContinuum system and the Gatan Alpine Vista direct electron detector, including supporting equipment

Electronic and Precision Equipment Repair and Maintenance

POSTED

DEADLINE

Notice of Intent to Sole Source – Miltenyi Biotec, Inc

Analytical Laboratory Instrument Manufacturing

POSTED

DEADLINE

DNCSB group – Bonifacino group equipment maintenance (5 instruments- INFORS shkaers, Calorimeter and AKTA purifier)

Electronic and Precision Equipment Repair and Maintenance

POSTED

DEADLINE

Humanized single domain antibodies for therapeutic brain delivery

POSTED

DEADLINE

Notice of Intent to Sole Source – Lori Carson Consulting LLC

All Other Professional, Scientific, and Technical Services

POSTED

DEADLINE

Notice of Intent to Sole Source – Stryker Sales, LLC.

Surgical and Medical Instrument Manufacturing

POSTED

DEADLINE

Union for International Cancer Control (UICC) Technical Fellowship Program

Professional and Management Development Training

POSTED

DEADLINE

NOI - Neuropsychometric Evaluations Using the CDR

Offices of Physicians (except Mental Health Specialists)

POSTED

DEADLINE

Notice of Intent to Sole Source – 10x Genomics, Inc.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Specialized Disposable GlovesThe National Institutes of Health, under the Department of Health and Human Services, is seeking information on the availability of small business sources capable of supplying specialized disposable gloves required for high-risk clinical, research, laboratory, animal care, and facility-support operations. This sources sought notice, identified by solicitation number 75N98026SS00813, is not a solicitation for proposals or binding contract issuance but aims to identify qualified small business manufacturers, particularly those that are HUBZone, 8(a), veteran-owned, woman-owned, or service-disabled veteran-owned, operating under the NAICS code 315990 with a 500-employee size standard. The focus is on U.S.-manufactured gloves meeting exacting technical specifications for hazard protection, including sterile and non-sterile nitrile, neoprene, and polyisoprene varieties with extended cuffs, specific thicknesses, colors, and certifications for chemical and biological exposure—including compliance with ASTM D6978 for chemotherapy drug resistance. Requirements include gloves with 6 mil thickness and 12-inch cuffs for BSL-3 labs, powder-free medical-grade gloves with Aloe-Touch ICE coating, and documented permeation and degradation testing results. Respondents must be small businesses as defined by the NAICS code and must submit a capability statement electronically by 1:00 p.m. EDT on August 5, 2026, to Tonia Alexander at tonia.alexander@nih.gov with the specified subject line. Responses must include the legal business name, UEI number, point of contact details, size and socioeconomic status, country of origin for all materials, country of manufacture, and annual production capacity per glove type. Visuals and detailed product descriptions are encouraged, but no proprietary, confidential, or classified information should be included. All submissions are non-binding and will not be reimbursed. The goal is to ensure reliable, domestically produced access to critical personal protective equipment necessary for safeguarding personnel and maintaining uninterrupted operations across the Department’s public health and scientific missions.

Apparel Accessories and Other Apparel Manufacturing

POSTED

DEADLINE

Logiq E R9 Vet Console with CWD with accessories

Analytical Laboratory Instrument Manufacturing

POSTED

DEADLINE

Preventive Maintenance for the Gatan Alpine Direct Electron Detector

Electronic and Precision Equipment Repair and Maintenance

POSTED

1 day ago

DEADLINE

in 13 days

View Details